NovaBay Pharmaceuticals, Inc.
NBY
$0.58
-$0.02-3.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -10.12M | -10.66M | -11.12M | -9.64M | -13.74M |
| Total Depreciation and Amortization | 336.00K | 336.00K | 310.00K | 311.00K | 384.00K |
| Total Amortization of Deferred Charges | 1.44M | 1.96M | 2.11M | 1.69M | 1.12M |
| Total Other Non-Cash Items | 3.90M | 4.62M | 4.60M | 3.69M | 6.63M |
| Change in Net Operating Assets | -287.00K | 712.00K | -199.00K | -186.00K | 576.00K |
| Cash from Operations | -4.73M | -3.03M | -4.30M | -4.13M | -5.03M |
| Capital Expenditure | -8.00K | -7.00K | -7.00K | -18.00K | -16.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 1.07M | 1.07M | 1.07M | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 1.06M | 1.06M | 1.06M | -18.00K | -16.00K |
| Total Debt Issued | 0.00 | 0.00 | 3.00M | 3.00M | 3.00M |
| Total Debt Repaid | -2.69M | -2.48M | -2.05M | -1.47M | -770.00K |
| Issuance of Common Stock | 3.67M | 791.00K | 565.00K | 565.00K | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 3.04M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.00K | -2.00K | -200.00K | -181.00K | -294.00K |
| Cash from Financing | 974.00K | -1.69M | 1.31M | 1.91M | 4.97M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -277.00K | -293.00K | -293.00K | -293.00K |
| Net Change in Cash | -2.70M | -3.94M | -2.22M | -2.53M | -365.00K |
